Regional variability in anaemia management and haemoglobin in the US

Nephrology Dialysis Transplantation

Volumn 18, Issue 1, 2003, Pages 147-152

  Reddan, Donal N ^a   Frankenfield, Diane L ^b   Klassen, Preston S ^a   Coladonato, Joseph A ^a   Szczech, Lynda ^a   Johnson, Curtis A ^c   Besarab, Anatole ^d   Rocco, Michael ^e   McClellan, William ^f   Wish, Jay ^g   Owen Jr , William F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Center for Medicare and Medicaid Services   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anaemia; Centers for Medicare Medicaid Services; End stage renal disease; Erythropoietin; Haemodialysis; Iron

Indexed keywords

ALBUMIN; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS MEMBRANE; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZATION; SEX DIFFERENCE; UNITED STATES;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GEOGRAPHY; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICAID; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; UNITED STATES;

EID: 12244297159     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/18.1.147     Document Type: Article

References (22)

1. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37: S182-S238
2. Macdougall IC, Cavill I, Hulme B et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 1992; 304: 225-226
3. Cotter DJ, Thamer M, Kimmel PL, Sadler JH. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996. Kidney Int 1998; 54: 2129-2139
4. Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WE. Anemia management of adult, hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project. Kidney Int 2000; 57: 578-589
5. Madore F, Lowrie EG, Brugnara C et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8: 1921-1929
6. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583
7. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79: 299-305
8. Depner TA, Rizwan S, James LA. Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis. ASAIO Transactions 1990; 36: M223-M225
9. Health Care Financing Administration. Annual Report ESRD Clinical Performance Measures Project. Department of Health and Human Services Health Care Financing Administration Office of Clinical Standards and Quality, Baltimore, MD, December 1999
10. Frankenfield DL, McClellan WM, Helgerson SD, Lowrie EG, Rocco MV, Owen WE, Jr. Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core Indicators Project. Am J Kidney Dis 1999; 33: 584-591
11. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
12. Norusis MJ. SPSS for Windows, Advanced Statistics, Release 8.0. Chicago: Prentice Hall; 1997
13. U.S. Renal Data System. USRDS 1999 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 1999
14. Jacobs C. Treatment of anemia in dialysis patients in France (1998-1999) (Study by ESAM-France). Nephrologie 2002; 23: 85-91
15. Besarab A. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration. Am J Kidney Dis 1993; 22: 13-22
16. Paganini EP, Eschbach JW, Lazarus JM et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 1995; 26: 331-340
17. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
18. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney, Dis 1995; 26: 41-46
19. Coladonato JA, Frankenfield DL, Reddan DN et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002; 13: 1288-1295
20. Hynes DM, Stroupe KT, Greer JW et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002; 112: 169-175
21. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for mprovement. J Am Med Assoc 1999; 282: 1458-1465
22. Powe NR, Thamer M, Hwang W et al. Cost-quality trade-offs in dialysis care: a national survey of dialysis facility administrators. Am J Kidney Dis 2002; 39: 116-126